Noveeda

Executive Summary

Noveeda is a private biopharmaceutical company headquartered in Prague, Czech Republic, founded in 2018. The company specializes in developing novel, needle-free drug delivery technologies for emergency and life-threatening conditions. By repurposing existing pharmaceutical molecules and applying innovative formulation techniques, Noveeda aims to create patient-friendly administration methods that enable rapid onset of action in critical settings. This approach addresses key limitations of traditional injectables, such as needle phobia, need for trained personnel, and risk of needle-stick injuries. Noveeda's pipeline focuses on conditions where time-to-treatment is crucial, potentially improving outcomes for patients with anaphylaxis, opioid overdose, or seizures. The company's platform technology has broad applicability across multiple therapeutic areas, offering a competitive advantage in the growing needle-free drug delivery market. Despite being privately held and in early stages of development, Noveeda has established a strong intellectual property foundation and is advancing its lead candidates toward preclinical and clinical studies. The company's strategy of repurposing approved molecules reduces development risk and accelerates timelines compared to novel chemical entities. Key challenges include securing funding for clinical trials, building strategic partnerships for manufacturing and commercialization, and demonstrating bioequivalence and safety in human studies. If successful, Noveeda's platform could transform the standard of care for acute emergencies, offering a safer, more convenient alternative to injections. The company's progress will depend on near-term milestones such as completing IND-enabling studies and initiating first-in-human trials.

Upcoming Catalysts (preview)

• TBDCompletion of IND-enabling studies for lead candidate50% success
• Q1 2027First-in-human clinical trial initiation for needle-free epinephrine35% success
• Q4 2026Strategic partnership agreement for commercialization of platform25% success